skip to Main Content

News

Next symposium 11th and 12th of May

During this meeting the consortium will present it’s progress and several postdocs and PhD-students will show their research. On day 1 we also have a lecture by keynote speaker Claudia Mauri.

Program day 1

10:15 – 11:15   keynote lecture Claudia Mauri, UCL London (Title:  Regulatory B cells in Autoimmunity)

11:20- 12:35    Update from the WPs

12:35- 12:40   Closing of day 1 (Reina Mebius)

Program day 2

9:05-9:20   Luuk Wietske, AMC Update on COVID study

9:20-9:40    Marieke van Ham, Sanquin  SARS-CoV2-specific B cell responses

9:40-10:00   Mikhail Volkov, LUMC Comprehensive overview of pathogenic autoantibody isotype and subclass distribution

10:00-10:10   Break

10:10-10:30   Laurent Paardekooper, LUMC   Immunophenotyping of IgG4-mediated autoimmune disease

10:30-10:50   Jana Koers, Sanquin Autoantibody Fab glycosylation in autoimmune disease

10:50-11:10   Esther Vletter, LUMC  Immunoglobulin variable domain glycosylation affects autoreactive B cell (-and possibly Follicular Lymphoma cell-) activation and is predictive for disease development in rheumatoid arthritis

11:10-11:20    Break

11:20-11:40    Sabrina Pollastro, Sanquin  Performing BCR sequencing within TTB consortium

11:40-11:55    Taco Kuijpers Immuno Health XL brief update

11:55-12:00   Rene Toes Extra budget announcement

12:00-12:20    Time for discussion

12:20-12:25   Closing

Read more about our upcoming symposium
Get an update on our vaccination study
Read about the publication of our PAR-member NVLE (Wendy Zacouris amongst other)
Spotlight on one of the projects granted trough a budget application

Hydroxychloroquine treatment in European patients with Lupos erythematosus: dosing, retinopathy screening and adherence “ is a publication of Wendy Zacouris of the NVLE amongst others. The NVLE participates in our patient advisory board.  We invite you to read the publication.

Read more

WP1

In the Netherlands a range of scientists and clinicians are actively involved in B cell-related research...
Read more

WP2 and WP5

WP2 is dedicated to set-up specialized cellular assays to study the dynamics, diversity and function of B-lymphocyte differentiation in health...
Read more

WP3 and WP6

In workpackage 3 we try to understand the impact of B cell targeted therapy on the repertoire of autoantibodies with respect to...
Read more

WP4

Next to its scientific and clinical ambition, the consortium also aims to develop an outreach program for multiple stakeholders...
Read more

WP7 and WP8

Work package 7 is all about B cell-targeting therapies in B cell-mediated autoimmune diseases and malignancies...
Read more
Back To Top